English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Tamoxifen (TAM) resistance to invasive lobular cell carcinoma is a challenge for breast cancer treatment. This study explored the role of Aldo-keto reductase family 1 (AKR1) family in tamoxifen-resistant aggressive lobular breast cancer based on data mining. Methods TAM-resistant invasive lobular breast cancer gene chip was downloaded from the Gene Expression Omnibus (GEO) database (accession-numbered as GSE96670). The online analytical tool GEO2R was used to screen for differentially expressed genes in TAM-resistant invasive lobular breast cancer cells and TAM-sensitive counterparts. A protein-protein interaction (PPI) networks were constructed using the STRING online platform and the Cytoscape software. GeneMANIA and GSCALite online tools were used to reveal the potential role of these hub genes in breast cancer progression and TAM resistance development. And the used the GSE67916 microarray data set to verify the differentially expression of these hub genes in breast cancer. The protein expression levels of  AKR1C1 ,  AKR1C2  and  AKR1C3  in TAM-sensitive and resistant breast cancer cells were compared. The TAM sensitivity of breast cancer cells with or without  AKR1C1 ,  AKR1C2  or  AKR1C3  gene manipulation was evaluated by cell viability assay. Results A total of 184 differentially expressed genes were screened. Compared with TAM sensitive breast cancer cells, 162 were up-regulated and 22 were down-regulated. The study identified several hub genes in the PPI network that may be involved in the development of TAM resistance of breast cancer, including signal transducer and activator of transcription 1 ( STAT1 ), estrogen receptor alpha ( ESR1 ), fibronectin1 ( FN1 ), cytochrome P4501B1 ( CYP1B1 ),  AKR1C1 ,  AKR1C2 ,  AKR1C3  and uridine diphosphate glucuronosyltransferase ( UGT ) 1A family genes ( UGT1A1 ,  UGT1A 3,  UGT1A4 ,  UGT1A6 ,  UGT1A7 ,  UGT1A8 ,  UGT1A9 ,  UGT1A10 ). Compared with TAM-sensitive counterparts, the expression levels of  AKR1C1 ,  AKR1C2 , and  AKR1C3  were up-regulated in TAM-resistant breast cancer cells. Conclusions Overexpression of each of these three genes significantly increased the resistance of breast cancer cells to TAM treatment, while their knockdown showed opposite effects, indicating that they are potential therapeutic target for the treatment of TAM-resistant breast cancer.

The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining